Compare
Wave Life Sciences, Inc. vs Xilio Therapeutics, Inc. vs Biofrontera Inc. vs Cumberland Pharmaceuticals Inc
| Latest fiscal year | Wave Life Sciences, Inc. WVE | Xilio Therapeutics, Inc. XLO | Biofrontera Inc. BFRI | Cumberland Pharmaceuticals Inc CPIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $42.73M | $43.77M | $41.70M | $44.52M |
| Revenue growth (YoY) | -60.5% | +589.9% | +11.7% | +17.6% |
| Gross margin | n/a | n/a | n/a | 85.0% (computed) |
| Operating margin | -504.1% | -95.9% | -27.2% | -6.3% |
| Net margin | -478.3% | -80.1% | -25.3% | -6.4% |
| Net income | -$204.38M | -$35.04M | -$10.54M | -$2.84M |
| EPS (Diluted) | -$1.21 | -$4.19 | -$1.04 | -$0.19 |
| Operating cash flow | -$187.49M | -$4.99M | -$13.36M | $4.93M |
| Free cash flow | -$188.21M | -$5.51M | -$13.36M | $4.83M |
| Cash & equivalents | $602.07M | $137.53M | $6.39M | $11.44M |
| Total assets | $638.50M | $154.69M | $28.56M | $76.82M |
| Total liabilities | $112.27M | $119.41M | $18.08M | $52.28M |
| Shareholders' equity | $518.36M | $35.27M | $10.48M | $24.88M |
| Return on year-end equity | -39.4% | -99.3% | -100.5% | -11.4% |
| Shares outstanding | 187.66M | 4.53M | 11.65M | 14.96M |
Revenue, most recent five fiscal years
| Fiscal year | Wave Life Sciences, Inc. | Xilio Therapeutics, Inc. | Biofrontera Inc. | Cumberland Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $42.73M Ended 2025-12-31 | $43.77M Ended 2025-12-31 | $41.70M Ended 2025-12-31 | $44.52M Ended 2025-12-31 |
| 1 year earlier | $108.30M Ended 2024-12-31 | $6.34M Ended 2024-12-31 | $37.32M Ended 2024-12-31 | $37.87M Ended 2024-12-31 |
| 2 years earlier | $113.31M Ended 2023-12-31 | n/a | $34.07M Ended 2023-12-31 | $39.55M Ended 2023-12-31 |
| 3 years earlier | $3.65M Ended 2022-12-31 | n/a | $28.67M Ended 2022-12-31 | $42.01M Ended 2022-12-31 |
| 4 years earlier | $40.96M Ended 2021-12-31 | n/a | $24.10M Ended 2021-12-31 | $35.05M Ended 2021-12-31 |